Mitigating hERG Inhibition: Design of Orally Bioavailable CCR5 Antagonists as Potent Inhibitors of R5 HIV-1 Replication.
Skerlj R, Bridger G, Zhou Y, Bourque E, McEachern E, Danthi S, Langille J, Harwig C, Veale D, Carpenter B, Ba T, Bey M, Baird I, Wilson T, Metz M, MacFarland R, Mosi R, Bodart V, Wong R, Fricker S, Huskens D, Schols D.
Skerlj R, et al. Among authors: huskens d.
ACS Med Chem Lett. 2012 Jan 25;3(3):216-21. doi: 10.1021/ml2002604. eCollection 2012 Mar 8.
ACS Med Chem Lett. 2012.
PMID: 24900457
Free PMC article.